Press Releases Detail:
Avitar's Dr. Christine M. Moore Elected to Society for Hair Testing Board of Directors
July 11, 2000
CANTON, MA, July 11, 2000–Avitar, Inc. (AMEX: AVR) announced today that Christine M. Moore, Ph.D., C.Chem, M.R.S.C., DABCC, FACB, has been elected to the Society for Hair Testing (SOHT) Board of Directors, effective June 2000. Dr. Moore’s efforts to advance forensic toxicology, which has been focused on the detection of drugs in hair, will now be enhanced by her leadership in the Society for Hair Testing. This new role will raise Dr. Moore’s international visibility in her outreach to scientists from major industrialized nations that use hair testing for intensive drug investigations.
"Dr. Moore’s dedication to hair testing in forensic toxicology has been rewarded by this new prestigious leadership role. We are proud to see one of our senior managers acknowledged by her peers," said Peter Phildius, Chairman and Chief Executive Officer of Avitar.
"I am honored that the Society for Hair Testing has given me this opportunity to exchange information with my European colleagues on new hair testing methods and technologies. In addition, I can educate my peers in Germany, Luxembourg, Spain and Sweden on how current legislation affects hair testing used by the US government and businesses," said Dr. Christine Moore, Vice President of Laboratory Operations and Laboratory Director of United States Drug Testing Laboratories, Inc. (USDTL).
Dr. Moore joined USDTL, a subsidiary of Avitar, Inc., in 1994. She earned her Ph.D. in Forensic Toxicology at the University of Glasgow, Scotland. Dr. Moore presently presides as President Elect of the Mid-West Association for Toxicology & Therapeutic Drug Monitoring. In addition, she chairs the Continuing Education Committee of Society of Forensic Toxicologists (SOFT), and is a member of the American Academy of Forensic Sciences (AAFS), and the International Association-Forensic Toxicologists (TIAFT). Dr. Moore has testified as an expert witness in recent Congressional hearings investigating problems and advantages of hair and oral fluid as possible matrices for federal drug testing programs. Her work has appeared in over fifty-five publications including Journal of Forensic Science and Journal of Annals of Toxicology.
Avitar, Inc. (AMEX: AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreenTM, the world’s first rapid point-of-contact oral fluid test for drugs of abuse, HAIRscreenTM, a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices.
Avitar, Inc. (AMEX:AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreenTM, the world’s first rapid point-of-contact oral fluid test for drugs of abuse, HAIRscreenTM, a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. Avitar also markets an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices. For more information, see Avitar’s website at avitarinc.com.
This release forward looking statements that are subject to risks and uncertainties, including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
|
